SEGMENT REPORTING |
We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief operating officer- decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. Our chief operating officer- decision maker evaluates segment performance to the GAAP measure of gross profit.
| |
| Three
Months | |
| |
| Ended
| | |
| April
30, | |
| |
| 2025 | | |
| 2024 | |
| |
| | | |
| | |
Net sales | |
| | | |
| | |
Pocono
Pharmaceuticals | |
$ | 667,432 | | |
$ | 408,532 | |
4P Therapeutics | |
| - | | |
| - | |
| |
| 667,432 | | |
| 408,532 | |
Gross profit | |
| | | |
| | |
Pocono Pharmaceuticals | |
| 251,981 | | |
| 164,786 | |
4P Therapeutics | |
| - | | |
| - | |
| |
| 251,981 | | |
| 164,786 | |
Operating expenses | |
| | | |
| | |
Selling,
general and administrative-Pocono Pharmaceuticals | |
| 151,528 | | |
| 154,394 | |
Selling,
general and administrative-4P Therapeutics | |
| 19,999 | | |
| 24,354 | |
Selling,
general and administrative-Corporate | |
| 810,525 | | |
| 900,980 | |
Research
and development-4P Therapeutics | |
| 683,426 | | |
| 974,535 | |
| |
| 1,665,478 | | |
| 2,054,263 | |
Depreciation and Amortization | |
| | | |
| | |
Pocono Pharmaceuticals | |
$ | 48,213 | | |
$ | 56,823 | |
Corporate | |
| - | | |
| 3,011 | |
4P Therapeutics | |
| 9,267 | | |
| 9,267 | |
| |
$ | 57,480 | | |
$ | 69,101 | |
The following table presents information
about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.
| |
Three Months | |
| |
Ended | |
| |
April 30, | |
| |
2025 | | |
2024 | |
Net sales | |
| | | |
| | |
United States | |
$ | 667,432 | | |
$ | 408,532 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 667,432 | | |
$ | 408,532 | |
| |
| April
30, | | |
| January
31, | |
| |
| 2025 | | |
| 2025 | |
Property and equipment, net of accumulated depreciation | |
| | | |
| | |
United States | |
$ | 658,073 | | |
$ | 695,063 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 658,073 | | |
$ | 695,063 | |
Assets | |
| | | |
| | |
Corporate | |
$ | 2,869,688 | | |
$ | 4,205,577 | |
Pocono Pharmaceuticals | |
| 1,427,893 | | |
| 1,404,285 | |
4P Therapeutics | |
| 1,854,600 | | |
| 1,859,793 | |
| |
$ | 6,152,181 | | |
$ | 7,469,655 | |
|
We organize and manage our business
by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and
Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate
financial information is available and regularly reviewed by our chief officer decision maker, who is our chief executive officer, in
making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure
of gross profit.
| |
Years Ending January 31, | |
| |
2025 | | |
2024 | |
Net sales | |
| | |
| |
Pocono Pharmaceuticals | |
$ | 2,139,537 | | |
$ | 1,920,280 | |
4P Therapeutics | |
| - | | |
| 165,034 | |
| |
| 2,139,537 | | |
| 2,085,314 | |
Gross profit | |
| | | |
| | |
Pocono Pharmaceuticals | |
| 743,317 | | |
| 744,391 | |
4P Therapeutics | |
| - | | |
| 117,714 | |
| |
| 743,317 | | |
| 862,105 | |
Operating expenses | |
| | | |
| | |
Selling, general and administrative-Pocono Pharmaceuticals | |
| 661,805 | | |
| 606,275 | |
Selling, general and administrative-4P Therapeutics | |
| 136,294 | | |
| 236,953 | |
Selling, general and administrative-Corporate | |
| 3,515,711 | | |
| 2,930,378 | |
Goodwill and intangibles impairment | |
| 3,595,216 | | |
| - | |
Research and development-4P Therapeutics | |
| 3,119,134 | | |
| 1,960,425 | |
| |
| 11,028,160 | | |
| 5,734,031 | |
Depreciation and Amortization | |
| | | |
| | |
Pocono Pharmaceuticals | |
$ | 235,941 | | |
$ | 222,159 | |
Corporate | |
| 12,043 | | |
| 13,986 | |
4P Therapeutics | |
| 37,070 | | |
| 51,577 | |
| |
$ | 285,054 | | |
$ | 287,722 | |
The following table presents information
about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.
| |
Years Ending January 31, | |
| |
2025 | | |
2024 | |
Net sales | |
| | |
| |
United States | |
$ | 2,139,537 | | |
$ | 2,085,314 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 2,139,537 | | |
$ | 2,085,314 | |
| |
January 31, | | |
January 31, | |
| |
2025 | | |
2024 | |
Property and equipment, net of accumulated depreciation | |
| | |
| |
United States | |
$ | 695,063 | | |
$ | 774,924 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 695,063 | | |
$ | 774,924 | |
Assets | |
| | | |
| | |
Corporate | |
$ | 4,205,577 | | |
$ | 339,552 | |
Pocono Pharmaceuticals | |
| 1,404,585 | | |
| 5,079,293 | |
4P Therapeutics | |
| 1,859,793 | | |
| 2,098,309 | |
| |
$ | 7,469,955 | | |
$ | 7,517,154 | |
|